Tirzepatide vs Compounded Tirzepatide
A side-by-side research comparison of Tirzepatide and Compounded Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Tirzepatide | Compounded Tirzepatide |
|---|---|---|
| Full name | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) | Compounded Tirzepatide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Compounded medication |
| Mechanism | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. | Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss. |
| Molecular weight | 4,814 Da | 4813.45 Da |
| Half-life | 5 days (120 hours) | ~5 days |
| Bioavailability | High (SubQ ~80%) | ~80% subcutaneous |
| Typical dose | 2.5 mg → titrate up to 15 mg | 2.5-15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Compounded Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Dual incretin pathway activation
- Better muscle preservation
- Improved A1c
- Cardiovascular protection
- Reduced insulin resistance
Related comparisons
Research and educational reference only. Not medical advice.